Danaher Corporation Stock Price, News & Analysis

On July 25, 2022, Beckman Coulter announced a partnership with Massachusetts General Hospital to validate the Monocyte Distribution Width (MDW) biomarker for identifying severe pediatric infections. Funded by BARDA, the multi-center trial focuses on children under 15 with high fevers, aiming to enhance early detection of those at risk for hospitalization. This initiative leverages MDW's existing FDA clearance for adult sepsis, expanding its clinical utility in emergency departments, potentially allowing for quicker, informed treatment decisions without unnecessary testing.

Danaher Corporation (NYSE: DHR) reported its Q2 2022 results, showing net earnings of $1.7 billion or $2.25 per diluted share, a 1.5% decrease year-over-year.

However, non-GAAP adjusted diluted net earnings increased by 12% to $2.76 per share. Revenues rose 7.5% to $7.8 billion, with a core revenue growth of 9.5%. Operating cash flow stood at $2.0 billion, while non-GAAP free cash flow reached $1.7 billion. For Q3, the company expects high-single digit growth in core revenue.

Nordson Corporation (Nasdaq: NDSN) announced a strategic realignment of its business segments effective August 1, 2022. The new structure includes three segments: Industrial Precision Solutions (IPS), Medical and Fluid Solutions (MFS), and Advanced Technology Solutions (ATS). This change aims to enhance visibility in growing medical and electronics platforms. In fiscal 2021, IPS generated approximately $1.2 billion, MFS $0.6 billion, and ATS $0.5 billion in revenues. The company remains focused on top-tier growth with a commitment to innovative solutions across diverse end markets.

Danaher Corporation (NYSE: DHR) has appointed Feroz Dewan to its Board of Directors, increasing the board size from thirteen to fourteen members. Dewan, currently CEO of Arena Holdings Management, brings extensive experience from Tiger Global Management and Silver Lake Partners. His appointment aims to enhance Danaher's financial acumen and technology expertise, as noted by Chairman Steven M. Rales. Danaher is committed to innovation in healthcare, environmental and applied markets, supported by a team of approximately 80,000 associates.

Danaher Corporation (NYSE: DHR) will host a webcast for its second quarter 2022 earnings conference call on July 21, 2022, starting at 8:00 a.m. ET. The call, anticipating a duration of approximately one hour, will be accessible via the Investors section of Danaher's website. A replay will be available post-call until August 4, 2022. The earnings press release, along with slide presentations, will be posted online from 6:00 a.m. ET on the day of the call.

SciEX, part of Danaher Corporation (NYSE:DHR), has launched Zeno SWATH DIA, enhancing biomarker discovery through improved sensitivity and speed. The new system can quantify up to 2x the proteins in cell and plasma samples, significantly boosting clinical test development. Researchers can achieve large population-scale proteomic studies in weeks with 5-minute run-times, optimizing costs and sample usage. This advancement is expected to drive new therapies and precision medicine, reflecting a significant step forward in translational OMICS research.

SCIEX, a member of Danaher Corporation (NYSE:DHR), has launched SCIEX OS software v3.0 at ASMS 2022, aiming to enhance laboratory efficiency and integration. The software supports their mass spectrometry portfolio and introduces features such as Zeno SWATH DIA and stMRM, promoting superior data quality and workflow enhancements. The new Central Administration Console simplifies project management and security, while accessibility has been boosted with support for nine languages, enabling a global reach.

Danaher Corporation (NYSE: DHR) has joined the Bespoke Gene Therapy Consortium (BGTC) to enhance the development of customized gene therapies for rare diseases. Launched in October 2021, the BGTC aims to create efficient, cost-effective resources for the research community. Collaborating with key health organizations, Danaher will contribute its significant expertise in genomic medicines through its subsidiaries, including Pall Corporation and Cytiva. This initiative seeks to address challenges in the current drug development model, facilitating faster and more affordable solutions for patients in need.

Danaher Corporation (NYSE: DHR) announced a quarterly cash dividend of $0.25 per share for its common stock, payable on July 29, 2022, to shareholders of record by June 24, 2022. Additionally, a dividend of $12.50 per share for its 5.00% Series B Mandatory Convertible Preferred Stock will be paid on July 15, 2022, to record holders by June 30, 2022. This reflects Danaher's commitment to returning value to its shareholders while maintaining its operational strengths across various markets.